Boston, MA. 15th April 2025
MaineHealth has adopted contingency management (CM) as an evidence-based strategy for treating stimulant use disorder. Contingency Management Innovations (CMI), the CM division of Q2i, offers advanced technology to address stimulant use challenges, particularly with methamphetamine and cocaine. By integrating CMI’s State Incentive Manager Solution (SIMS), the process is streamlined and secure.
CM motivates positive behavior by offering tangible rewards, such as gift cards for patients providing stimulant-free urine samples. These incentives encourage patients to stay engaged in their recovery and sustain progress.
Christine Wyman, Clinical Director of MaineHealth Mid Coast Hospital Comprehensive Addiction Psychiatry Services in Brunswick and Damariscotta, said, “In Maine, where stimulant use disproportionately affects underserved communities, CM offers a scalable and cost-effective solution. With SIMS, we celebrated the first group of patients completing the 26-week program, marking a milestone in improving recovery rates and reducing the societal impact of stimulant use disorder. The project sets a new standard for a ‘best-in-class intervention.’ Staff report that SIMS is easy to use, and clients are motivated by the rewards.”
“We are thrilled to offer this evidence-based solution and look forward to expanding its impact,” Wyman concluded.
Kristen Silvia, MD, of MaineHealth Comprehensive Addiction Medicine, noted, “For rural populations in Maine, where access to care and stigma are challenges, CM provides a practical framework to improve outcomes.” She added, “Staff are excited to add this intervention to their toolkit, with many saying it’s the most rewarding part of their job. Clinicians feel empowered by the evidence-based approach, and the project is now at four sites.”
Steve Jenkins, CEO of Q2i, stated, “We’re excited to see our technology making a difference in Maine, empowering healthcare teams and patients alike. It’s inspiring to witness more states adopting or expanding CM programs to support recovery and improve lives.” Jenkins continued, “This partnership between MaineHealth and Q2i is a step forward in combating stimulant use disorder and fostering healthier communities through innovation and collaboration.”
About Q2i
Q2i is a privately held digital health company specializing in evidence-based, innovative solutions. Our technologies enhance clinical care, increase engagement, and improve outcomes. As global leaders in technology-driven Contingency Management solutions, Q2i is driving healthcare innovation. Our division, Contingency Management Innovations (CMI), is the leading developer of AI-powered CM technology, transforming behavior reinforcement and clinical outcomes.
For more information, visit: Q2i.com.